Analysts/Institutional Investor Meet/Con. Call Updates

November 06, 2026 To, To, Listing Department, The National Stock Exchange of India BSE Limited Ltd. Phiroze Jeejeebhoy Towers, The Listing Department Dalal Street, Exchange Plaza, Mumbai – 400 001 Bandra – Kurla Complex, Ref: BSE Scrip Code: 544497 Mumbai – 400051, NSE Scrip Code: AHCL Subject: Outcome of Q2/H1 FY27 Earnings Conference Call - Transcript Dear Sir/Madam, In compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the transcript of the Company’s Q2/H1 FY27 Earnings Call held on November 03, 2026. The same is being made available on the website of the Company at www.anlon.in Kindly take the aforesaid information on record. You are requested to take the above information on your record. Thanking You. Yours Faithfully, For ANLON HEALTHCARE LIMITED PUNITKUMAR RASADIA MANAGING DIRECTOR DIN: 06696258 ANLON HEALTHCARE LIMITED CIN No.: L24230GJ2013PLC077543 REGISTERED OFFICE: 101/102, Silver Coin Complex, Opp. Crystal Mall, Kalawad Road, Rajkot-360005, Gujarat (INDIA) PHONE NO.: +91-7069690081/82 | Email: info@anlonhealthcare.com | www.anlon.in “Anlon Healthcare Limited Q2 H1 FY27 Earnings Conference Call” November 03, 2026 MANAGEMENT: MR. PUNITKUMAR RASADIA – CHAIRMAN AND MANAGING DIRECTOR – ANLON HEALTHCARE LIMITED MODERATOR: MR. DIVYA SHETHIA – X-B4 ADVISORY Page 1 of 16 Anlon Healthcare Limited November 03, 2026 Moderator: Ladies and gentlemen, good day, and welcome to the Q2 H1 FY27 Earnings Conference Call of Anlon Healthcare Limited, hosted by X-B4 Advisory. As a reminder, all participant lines will be in the listen-only mode and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during this conference call, please signal an operator by pressing star, then zero on your touch-tone phone. Please note that this conference is being recorded. I now hand the conference over to Mr. Divya Shethia from X-B4 Advisory. Thank you, and over to you. Divya Shethia: Thank you. Good evening, everyone, and welcome to the Q2 H1 FY27 Earnings Conference Call of Anlon Healthcare Limited. Today on this call, we have with us Mr. Punitkumar Rasadia, Chairman and Managing Director of the company. This conference call may contain forward-looking statements about the company, which are based on beliefs, opinions and expectations as of today. Actual results may differ. The statements are not guarantees of future performance and may involve risks and uncertainties that are difficult to predict. A detailed Safe Harbor statement is given on the second page of earnings presentation of the company, which has been uploaded on the stock exchange and company's website as well. With this, I now hand over the call to Mr. Punitkumar Rasadia for his opening remarks. Over to you, sir. Punitkumar Rasadia: Good evening, everyone, and warm welcome to Anlon Healthcare Limited's Q2 and H1 FY27 Earnings Conference Call. Thank you all for joining us today. As we step into another existing phase of our journey, I would like to take a moment to express my heartfelt gratitude to all our stakeholders, investors and partners for their continued trust and support. I hope you have had an opportunity to go through our investor presentation, which has been uploaded on the stock exchange as well as on our company's website. Let me now turn to the strategic progress during the period, which is important to understanding the transformation underway at Anlon. Anlon today operates through the parent company and 5 group entities spanning the pharmaceutical value chain. Apiqo Organics has opened an industrial and fine chemicals vertical as a new revenue stream outside pharmaceuticals, operating its own established product range. We are also planning to allocate part of its reactor capacity to backward integrated intermediates, which we expect to support profitability as this scales. Bizotic Lifescience provides ready-to- operate API capacity at a second manufacturing site, reducing the execution risk and timeliness associated with the greenfield capacity. Remember India, which is now Anlon Medicos marks our entry into finished dosage formulation with capabilities in tablet and capsule and access to over 30 formulation dossiers. And we Page 2 of 16 Anlon Healthcare Limited November 03, 2026 operate from Q3 FY27, taking us into domestic retail and hospital markets. During the period, we have further incorporated 2 new subsidiaries. Anlon Biologics has been established to develop and manufacture peptides, oligonucleotides, biosimilar and biological composition. And Anlon Medico to manufacture surgical implants and medical devices across trauma, spine and joints. Both have been structured separately given the distinct manufacturing technology and regulatory pathways involved. We expect first revenue from Anlon Medicos in Q2 FY28 and from Anlon Biologics in Q4 FY28. In terms of contribution during the half year, Anlon Healthcare on a stand-alone basis accounted for 44.6% of consolidated revenue, Apiqo Organics for 43.7% and Bizotic Lifescience for 11.7%. Within the Anlon stand-alone portfolio, API contributed 17.1% and intermediates 81.1% with the balance from nutraceutical and other products. Taken together, our installed manufacturing capacity across the group now stands at approximately 1,900 to 2,000 metric tonne per annum against 400 metric tonne per annum at our Anlon parent facility. Our greenfield expansion at Rajkot will add roughly 1,200 metric tonne per annum through 8 new clean lines commissioning in Q1 FY28, which will allow us to run 8 APIs simultaneously, a further 500 metric tonnes per annum of expansion is planned across the group. On the regulatory side, we have 21 DMFs filed with the global authorities. And we expect 5 to 7 of these products to commercialize during FY27. We are targeting 3 to 5 additional DMF filing this year and the launch of 7 new APIs across additional therapeutic categories. Our Ketoprofen DMF filing for the U.S. market is currently underway. In CDMO, we continue to develop 3 molecules for 2 global innovator companies, so validation quantities for the first molecule have been supplied and commercial supplies are targeted from Q3 FY27. The remaining 2 molecules are in validation with commercialization targeted between Q4 FY27 to Q1 FY28. I would reiterate that CDMO molecule typically takes a minimum of 3 to 4 years from development to commercial revenue, which is precisely what makes this relationship durable once established. We are also progressing our Loxoprofen topical gel for the Indian market. Regulatory filings are underway with CDSCO and DCGI with approval anticipated in FY28. The product is positioned against the diclofenac-based topicals that dominate the Indian pain relief market. And it takes us downstream into formulation level value on a molecule where we already control the chemistry and the key starting material. On the industry, I will be brief. The global API and CDMO market continue to benefit from rising outsourcing with 73% of novel drugs approval in 2025 involving outsourced API manufacturing. Supply chains are diversifying away from single country sourcing. And India remains the principal beneficiary of the China Plus One strategy supported by domestic policy on API manufacturing. Page 3 of 16 Anlon Healthcare Limited November 03, 2026 What matters more is where Anlon leaves within that opportunity? We are among the very few Indian manufacturers for Loxoprofen Sodium Dihydrate, Ketoprofen, Dexketoprofen trometamol, molecules with a concentrated global supplier base and high regulatory barriers to entry. We hold DMF approval from PMDA in Japan, NMPA in China and ANVISA in Brazil for Loxoprofen and CEP from EDQM in Europe for Ketoprofen. Loxoprofen is most prescribed NSAID in Japan. And we manufacture its key starting material, Loxoprofen Acid in-house. In this business, registration rather than price is [Showing first 8,000 characters — download PDF for full document]